PARPi’s aimed at DDR-deficiency in TNBC have been approved for patients with metastatic HER2-negative BC with an inherited BRCA1 or BRCA2 mutation previously treated with chemotherapy (NCT02000622 using Olaparib), and those with deleterious or suspected deleterious germline BRCA-mutated HER2-negative, locally advanced, or metastatic BC (NCT01945775 using Talazoparib). The gene discussed is BRCA2; the disease is breast cancer.